Inclusion Criteria:

- Diagnosed with either breast or gynecological cancer

- Receiving either AC-like or carboplatin-paclitaxel MEC

- Experienced at least 1 episode of vomiting or retching during the first 5 days
following cycle 1 of chemotherapy that was thought to be due to chemotherapy.
Received standard chemotherapy-induced nausea and vomiting (CINV) prophylaxis not
containing aprepitant or fosaprepitant

- No change in chemotherapy at cycle 2

- No change in cycle 1 antiemetic regimen at cycle 2

- Eastern Cooperative Oncology Group (ECOG) status 0-1

Exclusion Criteria:

- Requires increase in systemic corticosteroid therapy

- Used benzodiazepines or opiates in the 48 hours prior to cycle 2 chemotherapy

- Received or will receive radiation therapy to the abdomen or pelvis in the week prior
to visit 1 or in days 1-6 following chemotherapy

- Vomited in the 24 hours prior to Treatment Day 1

- Pregnant or breast-feeding

- Participating in a study with aprepitant or fosaprepitant or has taken an
investigational drug in the last 4 weeks

- Symptomatic central nervous system metastasis

- History of other malignancies in the last 2 years